Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis)

N/A

Report date: 2024/02/05 14:09:03

Base Information

Drug NameAnti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis)

Drug Alias NameAnti-c-kit humanised IgG1/κ antibody-maytansine conjugateAnti-proto-oncogene protein c-kit IgG1/kappa antibody-maitansine conjugateAnti-proto-oncogene protein c-kit IgG1/kappa antibody-maytansine conjugateLOP-628

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > SMCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsStem cell growth factor receptor inhibitors

TargetsStem cell growth factor receptorTubulin

Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumNetherlandsAustralia +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsSolid tumoursLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A